... aflibercept, a vascular endothelial growth factor decoy receptor protein (VEGF Trap), in combination with docetaxel, cisplatin, and 5-fluorouracil in patients with advanced solid tumors. Patients and Methods: Patients received 2, 4, or 6 mg/kg of intravenous aflibercept with docetaxel 75 mg/m 2 , cisplatin 75...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Antitumor ECyd RNA polymerase Solid tumors TAS-106 The great success of gemcitabine in combination with other...

.... Carboplatin Autologous bone marrow transplantation Solid tumors Cancer Oncology 1993;50(suppl 2):47-52 J.L. Pico3 A. Ibrahima L. Castagnaa / / / . Bourhisa A/. Chazarda D. Maraninchib 7.P. Droza Institut Gustave-Roussy, Department of Medicine, Villejuif; Institut Paoli-Calmette. Division of Hematology...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. pVMicroglobulin Carcinoembryonic antigen Solid tumors Tumor marker Oncology 45: 162-165 (1988) < 1988 S. Karger AG...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Macrophage activity Malignant melanoma Serum lysozyme Solid tumors Oncology 36: 15-18 (1979) Serum Lysozyme Levels in Patients with Solid...

...Hugh L. Davis, jr.; Donald B. Rochlin; Arthur J. Weiss; William L. Wilson; Neil C. Andrews; Robert Madden; Nell Sedransk Cytosine arabinoside was administered to 449 patients with a variety of solid tumors. The phase I study included doses of 0.8–3.5 mg/kg × 10 days, and a small number received 5...

...G.J. Hill, II; R.R. Larsen; Elaine M. Sas; B.I. Cohen; T.J. Irish; Elisabeth Kandel; J. Kogler Results of chemotherapy are presented in detail for 603 courses of therapy with 30 drugs in 400 consecutive patients with 22 types of solid tumors. An overall response rate of 20% was observed. The length...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Solid tumors Complications Cytotoxic drugs Hormones Clinical therapy Palliation Complete responses Experimental drugs 5 6 2009 Oncology 26: 206-222 (1972...

... in Solid Tumors of Childhood T. I. Lawhorn, H. H. Stone and J. D. Martin, jr. Joseph B. Whitehead Department of Surgery, Emory University School of Medicine, Atlanta, Ga. Abstract. Several malignant tumors are unique Key Words to infants and children. Earlier diagnosis, improved Chemotherapy surgical...

...) and the maximum-tolerated doses of the paclitaxel, oxaliplatin (LOHP) and capecitabine combination in patients with advanced solid tumors. Patients and Methods: Patients received escalating doses of paclitaxel (starting dose 100 mg/m 2 ) and LOHP (starting dose 40 mg/m 2 ) on days 1 and 15 and capecitabine...

... tumors. A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of their combination in patients with refractory solid tumors. Patients and Methods: Fifteen patients with histologically confirmed inoperable solid neoplasms were enrolled...

...S. Kakolyris; J. Souglakos; C. Kouroussis; N. Androulakis; G. Samonis; N. Vardakis; K. Amarantidis; S. Agelaki; D. Mavroudis; N. Xenidis; V. Georgoulias Objectives: Capecitabine (CAP) and oxaliplatin (OX) have shown interesting activity in a wide range of solid tumors. A phase I study was conducted...

... in patients with solid tumors receiving chemotherapy. We conducted a randomized, open label study to assess the efficacy of erythropoietin in preventing transfusions and significant anemia (hemoglobin <10 g/dl) in patients with solid tumors receiving platinum-based chemotherapy. Methods: One hundred forty...

...Walter J. Curran The institution of combined modality therapy for unresected solid tumors has resulted in significant improvements in tumor control and survival benefit compared with radiotherapy (RT) alone. A number of chemotherapy agents that can enhance the effectiveness of RT, such as cisplatin...

...S. Kakolyris; C. Kouroussis; M. Koukourakis; D. Mavroudis; K. Malas; N. Vardakis; V. Bozionelou; K. Kalbakis; V. Georgoulias Objectives: Vinorelbine (V) and oxaliplatin (OX) have shown interesting activity in a wide range of solid tumors. A phase I study was conducted in order to determine...

... favorable pharmacokinetic and toxicity profile than the free drug. We conducted a phase I study to determine the maximum tolerated doses (MTD) and the dose limiting toxicities (DLT) of the combination administered every 2 weeks in patients with advanced solid tumors. Patients and Methods: Treatment...

...S. Kakolyris; Ch. Kouroussis; J. Souglakos; D. Mavroudis; S. Agelaki; K. Kalbakis; N. Androulakis; N. Vardakis; L. Vamvakas; V. Georgoulias Objectives: Topotecan, a potent inhibitor of the enzyme topoisomerase I, has shown an interesting activity against several types of solid tumors, most notably...

... that is administered orally and has been rationally designed to generate 5-FU selectively within solid tumors. Theoretically, it has two major advantages, which should translate into an improved therapeutic index: firstly, enhanced drug concentration at the cancer site and therefore greater anti-tumor activity...

..., instructions or products referred to in the content or advertisements. Xeloda ® (capecitabine) 5-Fluorouracil Fluoropyrimidines Solid tumors Tumor-selective activation Oral chemotherapy 5-Fluorouracil (5-FU) is one of the most frequently used cytotoxic agents for the treatment of solid...